Our medical, nursing and allied health clinicians are increasingly involved in research to improve the care of our patients. This is reflected in the breadth of our research publications.
Opinions and practices of blood glucose control in critically ill patients with pre-existing type 2 diabetes in Australian and New Zealand intensive care units
Poole, AP; Anstey, J; Bellomo, R; Biradar, V; Deane, AM; Finfer, SR; Finnis, ME; French, CJ; Kar, P; Kruger, PS; Maiden, MJ; Martensson, J; McArthur, CJ; McGuinness, SP; Secombe, PJ; Tobin, AE; Udy, AA; Eastwood, GM
(2019), Aust. Crit. Care, 361-365
Pathophysiology and Treatment of Gastrointestinal Motility Disorders in the Acutely Ill
Deane, AM; Chapman, MJ; Blaser, AR; McClave, SA; Emmanuel, A
(2019), Nutr. Clin. Pract., 23-36
DOI: 10.1002/ncp.10199
What Happens to Nutrition Intake in the Post-Intensive Care Unit Hospitalization Period? An Observational Cohort Study in Critically Ill Adults
Ridley, EJ; Parke, RL; Davies, AR; Bailey, M; Hodgson, C; Deane, AM; McGuinness, S; Cooper, DJ
(2019), J. Parenter. Enter. Nutr., 88-95
DOI: 10.1002/jpen.1196
Gallbladder Dyskinesia Is Associated With an Impaired Postprandial Fibroblast Growth Factor 19 Response in Critically Ill Patients
Koelfat, KVK; Plummer, MP; Schaap, FG; Lenicek, M; Jansen, PLM; Deane, AM; Damink, SWMO
(2019), Hepatology, 308-318
DOI: 10.1002/hep.30629
Metabolic support in the critically ill: a consensus of 19
Wernerman, J; Christopher, KB; Annane, D; Casaer, MP; Coopersmith, CM; Deane, AM; De Waele, E; Elke, G; Ichai, C; Karvellas, CJ; McClave, SA; Oudemans-van Straaten, HM; Rooyackers, O; Stapleton, RD; Takala, J; van Zanten, ARH; Wischmeyer, PE; Preiser, JC; Vincent, JL
(2019), Crit. Care
A systematic review and meta-analysis of the effect of dispatcher-assisted CPR on outcomes from sudden cardiac arrest in adults and children
Nikolaou, N; Dainty, KN; Couper, K; Morley, P; Tijssen, J; Vaillancourt, C; Olasveegen, T; Mancini, MB; Travers, A; Lofgren, B; Nishiyama, C; Stanton, D; Ristagno, G; Considine, J; Castren, M; Smyth, M; Kudenchuk, P; Escalante, R; Gazmuri, R; Brooks, S; Chung, SP; Hatanaka, T; Perkins, G; Maconachie, I; Aickin, R; De Caen, A; Atkins, D; Bingham, R; Couto, TB; Guerguerian, AM; Meaney, P; Nadkarni, V; Ng, KC; Nuthall, G; Ong, YKG; Reis, A; Schexnayder, S; Shimizu, N; Van de Voorde, P
(2019), Resuscitation, 82-105
Access, knowledge and experience with fluorodeoxyglucose positron emission tomography/computed tomography in infection management: a survey of Australia and New Zealand infectious diseases physicians and microbiologists
Douglas, AP; Thursky, KA; Worth, LJ; Harrison, SJ; Hicks, RJ; Slavin, MA
(2019), Intern. Med. J., 615-621
DOI: 10.1111/imj.14117
Utilizing genomic analyses to investigate the first outbreak of vanA vancomycin-resistant Enterococcus in Australia with emergence of daptomycin non-susceptibility
Douglas, AP; Marshall, C; Baines, SL; Ritchie, D; Szer, J; Madigan, V; Chan, HT; Ballard, SA; Howden, BP; Buising, K; Slavin, MA
(2019), J. Med. Microbiol., 303-308
DOI: 10.1099/jmm.0.000916
Auditing fungal disease in leukemia patients in a tertiary care center: opportunities and challenges for an antifungal stewardship program
Paige, E; Haywood, P; Xie, MD; Worth, L; Thursky, K; Urbancic, K; Bajel, A; Slavin, M
(2019), Leuk. Lymphoma, 2373-2383
Why did we fail? Challenges recruiting parents with cancer into a psycho-educational support program
Stafford, L; Sinclair, M; Newman, L; Rauch, P; Barton, M; Gilham, L; Cannell, J; Mason, K; Joubert, L; Hocking, A; Little, R
(2019), Psycho-Oncol., 2425-2428
DOI: 10.1002/pon.5226
Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study
Bromberg, JEC; Issa, S; Bakunina, K; Minnema, MC; Seute, T; Durian, M; Cull, G; Schouten, HC; Stevens, WBC; Zijlstra, JM; Baars, JW; Nijland, M; Mason, KD; Beeker, A; van den Bent, M; Beijert, M; Gonzales, M; de Jong, D; Doorduijn, JK
(2019), Lancet Oncol., 216-228
Anti-Xa levels with low molecular weight heparin calibrator can be used to exclude significant apixaban effect
Singh, J; Ong, DM; Wallis, A; Kelsey, G; Tran, H
(2019), Pathology, 768-769
Immunotherapeutics in Multiple Myeloma: How Can Translational Mouse Models Help?
Cooke, RE; Koldej, R; Ritchie, D
(2019), J. Oncol.
DOI: 10.1155/2019/2186494
Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia
Ross, DM; Pagani, IS; Irani, YD; Clarson, J; Leclercq, T; Dang, P; McLean, J; Saunders, VA; Carne, L; Reynolds, J; Ritchie, DS; White, DL; Branford, S; Hughes, TP; Yong, ASM
(2019), Br. J. Haematol., E56-E60
DOI: 10.1111/bjh.15894
Recipient BCL2 inhibition and NK cell ablation form part of a reduced intensity conditioning regime that improves allo-bone marrow transplantation outcomes
Jiao, YH; Davis, JE; Rautela, J; Carrington, EM; Ludford-Menting, MJ; Goh, W; Delconte, RB; Souza-Fonseca-Guimaraes, F; Koldej, R; Gray, D; Huang, D; Kile, B; Lew, AM; Ritchie, DS; Huntington, ND
(2019), Cell Death Differ., 1516-1530
Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with Sezary syndrome
Gao, C; McCormack, C; van der Weyden, C; Goh, MS; Campbell, BA; Twigger, R; Buelens, O; Harrison, SJ; Khoo, C; Lade, S; Prince, HM
(2019), Blood, 1346-1350
Maintaining a fit T-cell compartment: lymphoma treatment sequencing in the era of chimeric antigen receptor T-cell therapies
Dickinson, M; Weinkove, R
(2019), Intern. Med. J., 1338-1338
DOI: 10.1111/imj.14453
Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission
Rashidi, A; Hamadani, M; Zhang, MJ; Wang, HL; Abdel-Azim, H; Aljurf, M; Assal, A; Bajel, A; Bashey, A; Battiwalla, M; Beitinjaneh, AM; Bejanyan, N; Bhatt, VR; Bolanos-Meade, J; Byrne, M; Cahn, JY; Cairo, M; Ciurea, S; Copelan, E; Cutler, C; Daly, A; Diaz, MA; Farhadfar, N; Gale, RP; Ganguly, S; Grunwald, MR; Hahn, T; Hashmi, S; Hildebrandt, GC; Holland, HK; Hossain, N; Kanakry, CG; Kharfan-Dabaja, MA; Khera, N; Koc, Y; Lazarus, HM; Lee, JW; Maertens, J; Martino, R; McGuirk, J; Munker, R; Murthy, HS; Nakamura, R; Nathan, S; Nishihori, T; Palmisiano, N; Patel, S; Pidala, J; Olin, R; Olsson, RF; Oran, B; Ringden, O; Rizzieri, D; Rowe, J; Savoie, ML; Schultz, KR; Seo, S; Shaffer, BC; Singh, A; Solh, M; Stockerl-Goldstein, K; Verdonck, LF; Wagner, J; Waller, EK; De Lima, M; Sandmaier, BM; Litzow, M; Weisdorf, D; Romee, R; Saber, W
(2019), Blood Adv., 1826-1836
Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations
Birkinshaw, RW; Gong, JN; Luo, CS; Lio, D; White, CA; Anderson, MA; Blombery, P; Lessene, G; Majewski, IJ; Thijssen, R; Roberts, AW; Huang, DCS; Colman, PM; Czabotar, PE
(2019), Nat. Commun.
A Retrospective Evaluation of Risk of Peripartum Cardiac Dysfunction in Survivors of Childhood, Adolescent and Young Adult Malignancies
Chait-Rubinek, L; Mariani, JA; Goroncy, N; Herschtal, A; Wheeler, GC; Dwyer, MK; Seymour, JF; Campbell, BA
(2019), Cancers
Pediatric aplastic anemia treatment patterns and responses; power in the numbers
Fox, LC; Ritchie, DS
(2019), Haematologica, 1909-1912
Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression
Seymour, JF; Marcus, R; Davies, A; Gallop-Evans, E; Grigg, A; Haynes, A; Herold, M; Illmer, T; Nilsson-Ehle, H; Sokler, M; Dunzinger, U; Nielsen, T; Launonen, A; Hiddemann, W
(2019), Haematologica, 1202-1208
Further Examining the TROG 99.03 Trial in Early-Stage Follicular Lymphoma: Cure Rate and the Role of Positron Emission Tomography Reply
MacManus, M; Fisher, R; McClure, B; Seymour, JF
(2019), J. Clin. Oncol., 257-+
Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study
Bachy, E; Seymour, JF; Feugier, P; Offner, F; Lopez-Guillermo, A; Belada, D; Xerri, L; Catalano, JV; Brice, P; Lemonnier, F; Martin, A; Casasnovas, O; Pedersen, LM; Dorvaux, V; Simpson, D; Leppa, S; Gabarre, J; da Silva, MG; Glaisner, S; Ysebaert, L; Vekhoff, A; Intragumtornchai, T; Le Gouill, S; Lister, A; Estell, JA; Milone, G; Sonet, A; Farhi, J; Zeuner, H; Tilly, H; Salles, G
(2019), J. Clin. Oncol., 2815-+
DOI: 10.1200/JCO.19.01073
Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study
Kater, AP; Seymour, JF; Hillmen, P; Eichhorst, B; Langerak, AW; Owen, C; Verdugo, M; Wu, J; Punnoose, EA; Jiang, YW; Wang, J; Boyer, M; Humphrey, K; Mobasher, M; Kipps, TJ
(2019), J. Clin. Oncol., 269-+
DOI: 10.1200/JCO.18.01580
GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia
Mehta, RS; Holtan, SG; Wang, T; Hemmer, MT; Spellman, SR; Arora, M; Couriel, DR; Alousi, AM; Pidala, J; Abdel-Azim, H; Ahmed, I; Aljurf, M; Askar, M; Auletta, JJ; Bhatt, V; Bredeson, C; Chhabra, S; Gadalla, S; Gajewski, J; Gale, RP; Gergis, U; Hematti, P; Hildebrandt, GC; Inamoto, Y; Kitko, C; Khandelwal, P; MacMillan, ML; Majhail, N; Marks, DI; Mehta, P; Nishihori, T; Olsson, RF; Pawarode, A; Diaz, MA; Prestidge, T; Qayed, M; Rangarajan, H; Ringden, O; Saad, A; Savani, BN; Seo, S; Shah, A; Shah, N; Schultz, KR; Solh, M; Spitzer, T; Szer, J; Teshima, T; Verdonck, LF; Williams, KM; Wirk, B; Wagner, J; Yared, JA; Weisdorf, DJ
(2019), Blood Adv., 1441-1449
The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia
Minson, AG; Cummins, K; Fox, L; Costello, B; Yeung, D; Cleary, R; Forsyth, C; Tatarczuch, M; Burbury, K; Motorna, O; Shortt, J; Fleming, S; McQuillan, A; Schwarer, A; Harrup, R; Holmes, A; Ratnasingam, S; Chan, KL; Hsu, WH; Ashraf, A; Putt, F; Grigg, A
(2019), Blood Adv., 1084-1091
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial
Zelenetz, AD; Salles, G; Mason, KD; Casulo, C; Le Gouill, S; Sehn, LH; Tilly, H; Cartron, G; Chamuleau, MED; Goy, A; Tam, CS; Lugtenburg, PJ; Petrich, AM; Sinha, A; Samineni, D; Herter, S; Ingalla, E; Szafer-Glusman, E; Klein, C; Sampath, D; Kornacker, M; Mobasher, M; Morschhauser, F
(2019), Blood, 1964-1976
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
Tam, CS; Trotman, J; Opat, S; Burger, JA; Cull, G; Gottlieb, D; Harrup, R; Johnston, PB; Marlton, P; Munoz, J; Seymour, JF; Simpson, D; Tedeschi, A; Elstrom, R; Yu, YL; Tang, ZY; Han, L; Huang, J; Novotny, W; Wang, L; Roberts, AW
(2019), Blood, 851-859
Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables
Roberts, AW; Ma, S; Kipps, TJ; Coutre, SE; Davids, MS; Eichhorst, B; Hallek, M; Byrd, JC; Humphrey, K; Zhou, L; Chyla, B; Nielsen, J; Potluri, J; Kim, SY; Verdugo, M; Stilgenbauer, S; Wierda, WG; Seymour, JF
(2019), Blood, 111-122